StemCells to Acquire UK's Stem Cell Sciences for Up to $4.85M to Build Drug-Discovery Play | GenomeWeb

StemCells plans to acquire certain assets of UK-based Stem Cell Sciences for as much as $4.85 million, the companies said this week.

As part of the deal, Palo Alto, Calif.-based StemCells plans to provide SCS with 2.65 million of its shares and approximately $715,000 in waived loan payments.

Expected to close within two months, the deal will see StemCells acquire SCS' R&D operations in Cambridge, UK, and a facility near Melbourne, Australia.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.